Research Identifies Growth Factor That Can Reverse Heart Attack Damage

by Thilaka Ravi on  July 25, 2009 at 5:13 PM Heart Disease News
RSS Email Print This Page Comment
Font : A-A+

Research Identifies Growth Factor That Can Reverse Heart Attack Damage
Researchers at Children's Hospital Boston have taken a significant step towards regenerating heart tissue after a heart attack, in patients with heart failure, or in children with congenital heart defects.

Normally, it is not possible to re-grow injured heart tissue, but researchers have shown that a growth factor, called neuregulin1 (NRG1), can spur heart-muscle growth and recovery of cardiac function when injected systemically into animals after a heart attack.

NRG1 is involved in the initial development of the heart and nervous system,

After birth, heart-muscle cells (cardiomyocytes) normally withdraw from the cell cycle, which means that they stop dividing and proliferating.

But the researchers, led by Dr. Bernhard Kuhn, and Dr. Kevin Bersell, were able to restart the cell cycle with NRG1, stimulating cardiomyocytes to divide and make copies of themselves, despite not being stem cells.

"Although many efforts have focused on stem-cell based strategies, our work suggests that stem cells aren't required and that stimulating differentiated cardiomyocytes to proliferate may be a viable alternative," said Kuhn.

When the team injected NRG1 into the peritoneal cavity of live mice after a heart attack, once daily for 12 weeks, heart regeneration was increased and pumping function (ejection fraction, assessed on echocardiograms) improved as compared with untreated controls.

The NRG1-injected mice also lacked the left-ventricular dilation and cardiac hypertrophy that typify heart failure-two conditions seen in the controls.

When the researchers also stimulated production of a cellular receptor for NRG1, known as ErbB4, cardiomyocyte proliferation was further enhanced, which showed that NRG1 works by stimulating this receptor.

They also identified the specific kinds of cardiomyocytes (mononucleated) that are most likely to respond to treatment.

In 2007, Kuhn developed a sponge-like patch, soaked in a compound called periostin, which when placed over the site of cardiac injury in rats, \induced cardiomyocyte proliferation and improved heart function.

The new study has revealed how both periostin and NRG-1 work at the cellular and molecular level, an essential step in predicting possible side effects.

Kuhn found that both compounds ultimately act on the same cellular pathway.

"We applied periostin locally at the site of cardiac injury, but NRG1 works when given by systemic injection - a very promising result that suggests it may be feasible to use this in the clinic to treat heart failure," said Kuhn.

The study has been published in the journal Cell.

Source: ANI
THK

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Chest Pain Cardiac Catheterization Heart Attack Diet Lifestyle and Heart Disease Coronary Artery Bypass Grafting Stress and the Gender Divide Heart Attack Facts Heart Heart Attack- Lifestyle Risks Healthy Heart 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive